Adolescent depression
Conditions
Interventions
Conventional Group:Repetitive transcranial magnetic stimulation of L-DLPFC, once daily, 5 times per week for 4 weeks
Combined Treatment Group:Morning repetitive transcranial magnetic stimulation of L-DLPFC, afternoon repetitive transcranial magnetic stimulation of the right cerebellar CrusI region, with more than 1
Cerebellar Stimulation Group:Repetitive transcranial magnetic stimulation of the right cerebellar CrusI region, once daily, 5 times per week for 4 weeks
Sham Stimulation Control Group:Sham stimulation using a sham coil with parameters matching the experimental group (no pulse output)
Sponsors
The Affiliated Xuzhou Eastern Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Age
13 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. Participants must be adolescents aged 13 to 18 years and meet the diagnostic criteria for depression according to the International Classification of Diseases, 10th Revision (ICD-10). 2. Score > 17 on the 17-item Hamilton Depression Scale (HAMD). 3. Minimum duration of depressive illness: 6 months. 4. Right-handedness. 5. During the study period, patients must maintain their current antidepressant treatment regimen unchanged. A stable antidepressant medication regimen must be maintained for at least 4 weeks prior to rTMS treatment, and patients must agree to keep their medication status stable during both the treatment and follow-up periods. 6. Voluntary participation of the patient or their legal guardian, with the ability to provide written informed consent.
Exclusion criteria
Exclusion criteria: 1. The patient’s primary psychiatric diagnosis is not depression, or they meet the diagnostic criteria for other mental disorders according to the International Classification of Diseases, 10th Revision (ICD-10). 2. History of acute suicidal or violent behavior, or suicide attempts within the past 4 weeks. 3. Presence of severe or unstable medical conditions, neurological disorders, or cognitive impairments that may interfere with the conduct of the current study. 4. Prior history of other non-invasive neuromodulation therapies (e.g., electroconvulsive therapy [ECT], repetitive transcranial magnetic stimulation [rTMS]) with >=5 sessions in the past 6 months. 5. Existence of specific contraindications to transcranial magnetic stimulation (TMS) or magnetic resonance imaging (MRI) (e.g., history of seizures, pacemakers, or metal implants). 6. Diagnosis of claustrophobia in the participant. 7. Inability to comply with the study visit schedule.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Depression Rating Scale (HAMD-17) Reduction Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Self-Rating Depression Scale (SDS) Score;Montreal Cognitive Assessment (MoCA) Total Score;Pittsburgh Sleep Quality Index (PSQI) Score;Amplitude of Low-Frequency Fluctuations (ALFF) and Regional Homogeneity (ReHo) Values;Functional Connectivity Strength between Dorsolateral Prefrontal Cortex (DLPFC) and Right Cerebellar Crus I (Seed-Based Functional Connectivity Analysis); | — |
Countries
China
Contacts
Public ContactWang Wei
The Affiliated Xuzhou Eastern Hospital of Xuzhou Medical University
Outcome results
None listed